Arbutus Biopharma Corp (ABUS)’s stock has witnessed a price hike of 1.58% from the previous close with its current price standing at $4.18. Its current price is -11.64% under its 52-week high of $4.72 and 147.04% more than its 52-week low of $1.69. Based on the past 30-day period, the stock price is -3.66% below the high and +14.79% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, ABUS’s SMA-200 is $3.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Additionally, it is important to take into account ABUS stock ratios, including its price-to-sales ratio, which is 78.35 for the last tewlve months.ABUS’s price to book ratio for the most recent quarter was 6.43, resulting in an 5.55 price to cash per share for the period.
How does Arbutus Biopharma Corp (ABUS) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 4 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 5.00 in simple terms.
Arbutus Biopharma Corp (ABUS): Earnings History
If we examine Arbutus Biopharma Corp’s recent earnings history, in the last quarter ended on 6/30/2024, it posted adjusted earnings per share of -$0.11, beating the consensus of -$0.1. In other words, it beat the consensus by -$0.01, resulting in a -10.00% surprise. In the 3 months period before the previous quarter which was closed on 6/30/2024, the stock recorded adjusted earnings per share of -$0.11 in contrast with the Outlook of -$0.1. That was a difference of -$0.01 and a surprise of -10.00%.
Arbutus Biopharma Corp (ABUS): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 2 different analysts, who are expecting earnings to fall in between the range of -0.08 and -0.11 with an average Earnings Estimate of -0.09 which is in contrast with the last year earnings estimate of -0.12 and also replicates 25.00% growth rate year over year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Ownership Details
I will give a breakdown of the key shareholders in Arbutus Biopharma Corp (ABUS). Recent figures show that the company’s insiders hold 22.30% of shares. A total of 176 institutional investors hold shares in the company, making 51.62% of its stock and 66.44% of its float.
Jun 30, 2024, it was reported that the Company’s largest institutional holder is Morgan Stanley holding total of 20.96 shares that make 11.10% of the company’s total number of shares and are currently priced at 87.3 million.
The securities firm Whitefort Capital Management, LP holds 12.87 shares of ABUS, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 6.82%, and the holding percentage of shares is valued at 53.6 million.
An overview of Arbutus Biopharma Corp’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Arbutus Biopharma Corp (ABUS) traded 1,238,448 shares per day, with a moving average of $3.91 and price change of +0.06. With the moving average of $3.96 and a price change of +0.57, about 1,183,077 shares changed hands on average over the past 50 days. Finally, ABUS’s 100-day average volume is 1,113,489 shares, alongside a moving average of $3.69 and a price change of +0.91.
